|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
Contemporary Management of Patients with Systemic Lupus Erythematosus: A Case-based Approac
This modular continuing education activity provides an update on the epidemiology, monitoring, and treatment of patients with systemic lupus erythematosus (SLE). Diane Kamen, MD, and Anca Askanase, MD, examine the current research on demographic groups with an increased risk of SLE and its severe complications, including lupus nephritis (LN). They also review the application of the most current treatment goals and classification criteria to speed diagnosis and guide disease activity monitorin... |
|
CME Escape Room: Putting Together Clues in HIV, CVD, T2D, and CKD: Escaping Management Mishaps
Target Audience
The educational design of this activity addresses the needs of US and ex-US infectious disease and HIV specialist physicians, NPs, and PAs involved in the treatment of patients with HIV.
Program Overview
As people with HIV live longer, they can develop common comorbidities affecting aging patients, such as type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD). Further, weight gain may be seen in some patients, though the role of antiretrovir... |
|
Thymidine Kinase 2 Deficiency: From Diagnostic Odyssey to Timely Diagnosis and Treatment
Mary Kay Koenig, MD, a leader in the management of patients with mitochondrial diseases, delves into the complexities of managing patients with thymidine kinase 2 deficiency (TK2d). In this 1-hour activity, Dr. Koenig shares her insights in the clinical presentation of TK2d through real case studies and offers guidance on overcoming the ‘diagnostic odyssey’ experienced by many patients with mitochondrial disease. She also discusses the clinical criteria for referring patients to specialize... |
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|
Nurses Light the Path: Empowering Patients to Improve Breast Cancer Screening and Clinical Trial Representation
Target Audience
The primary target audience for this activity is Oncology Nursing Professionals (APRN, NP, RN).
Program Overview
For women with breast cancer and those at risk, disparities in screening and clinical-trial enrollment exist, particularly among racial and ethnic minority populations. Awareness of these disparities can ensure timely screening practices and help address patient fears and concerns regarding clinical trials that inhibit diverse representation in research. Younger... |
|
Ethics for Occupational Therapists
Ethics for Occupational Therapists is a text-based, 3-hour online continuing education (CE/CEU) course that teaches OTs how to address ethical and moral dilemmas in practice.
Ethical and moral issues pervade our lives and healthcare professionals are constantly confronted with a variety of ethical and moral dilemmas. Decisions can have long-range effects professionally and personally, not only for the healthcare professional, but for patients, clients, healthcare entities, and society. Why ... |